- Home
- SNDL vs FHTX Comparison
SNDL vs FHTX Comparison
Compare SNDL & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNDL | FHTX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.3M | 332.2M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SNDL | FHTX |
|---|---|---|
| Price | $1.54 | $5.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $5.00 | ★ $11.71 |
| AVG Volume (30 Days) | ★ 897.6K | 103.0K |
| Earning Date | 01-01-0001 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,602,000.00 |
| Revenue This Year | $5.48 | $40.87 |
| Revenue Next Year | $3.41 | $11.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.15 | $2.94 |
| 52 Week High | $2.89 | $6.95 |
Technical Indicators
Market Signals| Indicator | SNDL | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 46.73 |
| Support Level | $1.44 | $4.44 |
| Resistance Level | $1.60 | $5.85 |
| Average True Range (ATR) | 0.06 | 0.33 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 46.23 | 39.43 |
Price Performance
Historical ComparisonAbout SNDL SNDL Inc.
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.